论文部分内容阅读
[目的]观察阿瑞匹坦预防阿霉素联合异环磷酰胺(AI)方案化疗后呕吐的疗效及安全性。[方法]将接受AI化疗方案的80例骨肉瘤和软组织肉瘤患者随机分为两组,阿瑞匹坦组予以三联(阿瑞匹坦、帕诺洛司琼、地塞米松)止吐方案、对照组予以二联(帕洛诺司琼、地塞米松)止吐方案,比较两组患者恶心、呕吐的控制情况,同时观察阿瑞匹坦的不良反应。[结果 ]急性观察期,阿瑞匹坦组和对照组的完全缓解(complete response,CR)率分别为84.6%和63.4%(P<0.05);迟发性观察期,阿瑞匹坦组CR率高于对照组(74.4%vs.51.2%,P<0.05);在总观察期,阿瑞匹坦组CR率亦显著性高于对照组(69.2%vs.46.3%,P<0.05);而两组的不良反应发生率无明显差异(P>0.05)。[结论]阿瑞匹坦联合帕洛诺司琼及地塞米松能有效预防AI化疗方案引起的恶心呕吐,且不良反应可耐受。
[Objective] To observe the efficacy and safety of aprepitant in preventing vomiting after adjuvant chemotherapy with doxorubicin and ifosfamide (AI). [Methods] Eighty patients with osteosarcoma and soft tissue sarcoma receiving AI chemotherapy were randomly divided into two groups. The aripipitan group was treated with triple therapy (aprepitant, palonosetron and dexamethasone) The control group was given dipyridamole (dexamethasone and dexamethasone) antiemetic. The nausea and vomiting were compared between the two groups, and the adverse reactions of aprepitant were observed. [Results] The complete response (CR) rates of aprepitant group and control group were 84.6% and 63.4% (P <0.05) respectively during the acute observation period. In the late observation period, CR (74.4% vs.51.2%, P <0.05). The CR rate in aprepitant group was also significantly higher than that in the control group during the observation period (69.2% vs.46.3%, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). [Conclusion] Both aprepitant combined with palonosetron and dexamethasone can effectively prevent nausea and vomiting induced by AI chemotherapy regimen, and the adverse reactions are tolerable.